{
    "nctId": "NCT00122070",
    "officialTitle": "Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder",
    "inclusionCriteria": "* Provide written informed consent before beginning any study related activities\n* Be between age 18 and 55 years\n* Be able to speak, read and write English and follow simple instructions for completing self-rated scales\n* Meet DSM-IV criteria for BPD as assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).\n* Must have minimum age of 18 Years\n* Must have maximum age of 55 Years",
    "exclusionCriteria": "* Are pregnant or lactating.\n* Have participated in any other studies involving investigational products within 30 days prior to entry into this study.\n* Are undergoing an acute withdrawal syndrome from drugs or alcohol.\n* Have an Axis I diagnosis of Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or Bipolar I Disorder as diagnosed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), and pertinent subsequent for ruling out exclusionary diagnoses.\n* Have an unstable medical disorder as determined by physical examination or laboratory testing. The primary investigator will be responsible for making this judgment based on the above.\n* Had an unsatisfactory response to a previous adequate trial of quetiapine as judged by a study investigator.\n* Patients cannot begin psychotherapy during the study period, but may continue if started prior to the study.\n* Patients who are currently receiving quetiapine therapy may not undergo a washout period and then restart quetiapine in the study."
}